Renaissance Technologies LLC purchased a new stake in Iqvia Holdings Inc (NYSE:IQV) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 523,047 shares of the medical research company’s stock, valued at approximately $51,206,000. Renaissance Technologies LLC owned about 0.25% of Iqvia as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Winslow Evans & Crocker Inc. acquired a new stake in Iqvia in the 4th quarter valued at $123,000. Focused Wealth Management Inc acquired a new stake in Iqvia in the 4th quarter valued at $166,000. Valeo Financial Advisors LLC acquired a new stake in Iqvia in the 4th quarter valued at $170,000. IFP Advisors Inc acquired a new stake in Iqvia in the 4th quarter valued at $200,000. Finally, Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in Iqvia in the 4th quarter valued at $209,000. Institutional investors own 92.34% of the company’s stock.
A number of equities analysts have weighed in on IQV shares. TheStreet raised shares of Iqvia from a “c+” rating to a “b” rating in a research report on Wednesday, December 13th. SunTrust Banks raised shares of Iqvia from a “hold” rating to a “buy” rating in a research report on Wednesday, March 7th. ValuEngine raised shares of Iqvia from a “hold” rating to a “buy” rating in a research report on Tuesday, February 20th. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a research report on Thursday, January 18th. Finally, Royal Bank of Canada set a $118.00 price target on shares of Iqvia and gave the stock a “buy” rating in a research report on Thursday, February 15th. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Iqvia presently has an average rating of “Buy” and an average target price of $110.02.
Shares of NYSE:IQV opened at $94.85 on Friday. Iqvia Holdings Inc has a 1-year low of $78.09 and a 1-year high of $110.67. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 1.21. The company has a market cap of $20,166.79, a P/E ratio of 21.75, a price-to-earnings-growth ratio of 1.40 and a beta of 0.63.
Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $1.34 by ($0.02). Iqvia had a return on equity of 13.03% and a net margin of 13.44%. The firm had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same period in the prior year, the business posted $1.09 EPS. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. sell-side analysts anticipate that Iqvia Holdings Inc will post 5.02 EPS for the current year.
In other news, insider James H. Erlinger III sold 10,000 shares of the firm’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $99.97, for a total transaction of $999,700.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Robert Parks sold 896 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $105.73, for a total transaction of $94,734.08. The disclosure for this sale can be found here. Insiders have sold a total of 21,712 shares of company stock valued at $2,176,034 in the last three months. Company insiders own 6.00% of the company’s stock.
WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/renaissance-technologies-llc-acquires-shares-of-523047-iqvia-holdings-inc-iqv.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.